Jesus Berdeja, MD, Sarah Cannon Center for Blood Cancers, Nashville, TN, highlights the exciting updates in multiple myeloma presented at ASH 2020, focusing on the advances in bispecific antibody therapies including products targeting BCMA, GPRC5D and FcRH5. These agents have yielded encouraging response rates and show impressive safety profiles. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.